MSB said it, and you have rightly pointed it out, the 3D manufacturing is to support commercial requirements,
If commercially there are only 300 orders, they do not require a bioreactor to generate 10,000 doses, or 100,000 doses.
When the commercial sales reaches a point where Bioreactor is required, then you can expect the company to go from using 2D to generate thousands of treatemnts, to 3D to generate 100's of thousands of treatments.
You've said MSB must have bioreactors to sell product, and they cannot afford to develop them without more money... which on the face of it there are no facts you have presented at all to back up either opinion. I'm more than happy they commercialise period, with or without 3D - as it's simply not needed at the point of commercialisation. After sales come in, demand goes up.... at a point then it would be a requirement.
priorities
2024 Here we go again., page-324
-
- There are more pages in this discussion • 620 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |